Brøsen K - Search Results

1

Lack of relationship between quinidine pharmacokinetics and the sparteine oxidation polymorphism.

Nielsen F, Rosholm JU, Brøsen K. Nielsen F, et al. Among authors: brosen k. Eur J Clin Pharmacol. 1995;48(6):501-4. doi: 10.1007/BF00194341. Eur J Clin Pharmacol. 1995. PMID: 8582470 Clinical Trial.

2

Inhibitors of imipramine metabolism by human liver microsomes.

Skjelbo E, Brøsen K. Skjelbo E, et al. Among authors: brosen k. Br J Clin Pharmacol. 1992 Sep;34(3):256-61. doi: 10.1111/j.1365-2125.1992.tb04133.x. Br J Clin Pharmacol. 1992. PMID: 1389950 Free PMC article.

3

The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy.

Sindrup SH, Bjerre U, Dejgaard A, Brøsen K, Aaes-Jørgensen T, Gram LF. Sindrup SH, et al. Among authors: brosen k. Clin Pharmacol Ther. 1992 Nov;52(5):547-52. doi: 10.1038/clpt.1992.183. Clin Pharmacol Ther. 1992. PMID: 1424428 Clinical Trial.

4

Lack of effect of mianserin on the symptoms of diabetic neuropathy.

Sindrup SH, Tuxen C, Gram LF, Grodum E, Skjold T, Brøsen K, Beck-Nielsen H. Sindrup SH, et al. Among authors: brosen k. Eur J Clin Pharmacol. 1992;43(3):251-5. doi: 10.1007/BF02333018. Eur J Clin Pharmacol. 1992. PMID: 1425887 Clinical Trial.

5

Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.

Nielsen KK, Brøsen K, Gram LF. Nielsen KK, et al. Among authors: brosen k. Eur J Clin Pharmacol. 1992;43(4):405-11. doi: 10.1007/BF02220617. Eur J Clin Pharmacol. 1992. PMID: 1451721 Clinical Trial.

6

Pharmacogenetics in psychopharmacology: basic principles and clinical implications.

Gram LF, Brøsen K, Sindrup S, Skjelbo E, Nielsen KK. Gram LF, et al. Among authors: brosen k. Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:76A-77A. Clin Neuropharmacol. 1992. PMID: 1499003 No abstract available.

7

Pharmacogenetics of tricyclic and novel antidepressants: recent developments.

Brøsen K, Gram LF, Sindrup S, Skjelbo E, Nielsen KK. Brøsen K, et al. Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:80A-81A. doi: 10.1097/00002826-199201001-00043. Clin Neuropharmacol. 1992. PMID: 1499005 No abstract available.

8

The relationship between paroxetine and the sparteine oxidation polymorphism.

Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A, Allen GD, Cooper SM, Mellows G, Tasker TC, et al. Sindrup SH, et al. Among authors: brosen k. Clin Pharmacol Ther. 1992 Mar;51(3):278-87. doi: 10.1038/clpt.1992.23. Clin Pharmacol Ther. 1992. PMID: 1531950

9

Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism.

Sindrup SH, Brøsen K, Gram LF. Sindrup SH, et al. Among authors: brosen k. Clin Pharmacol Ther. 1992 Mar;51(3):288-95. doi: 10.1038/clpt.1992.24. Clin Pharmacol Ther. 1992. PMID: 1531951

10

Drug related admissions to medical wards: a population based survey.

Hallas J, Gram LF, Grodum E, Damsbo N, Brøsen K, Haghfelt T, Harvald B, Beck-Nielsen J, Worm J, Jensen KB, et al. Hallas J, et al. Among authors: brosen k. Br J Clin Pharmacol. 1992 Jan;33(1):61-8. doi: 10.1111/j.1365-2125.1992.tb04001.x. Br J Clin Pharmacol. 1992. PMID: 1540492 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results